Research Portal

All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

Research output: Book/Report › Commissioned report

Standard Standard

All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate. / Hughes, D.; Hughes, D.A.; All Wales Strategy Group., [No Value].
2008 ed. Unknown, 2008.

Research output: Book/Report › Commissioned report

HarvardHarvard

Hughes, D, Hughes, DA & All Wales Strategy Group., NV 2008, All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate. 2008 edn, Unknown.

APA

Hughes, D., Hughes, D. A., & All Wales Strategy Group., N. V. (2008). All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate. (2008 ed.) Unknown.

CBE

Hughes D, Hughes DA, All Wales Strategy Group. NV 2008. All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate. 2008 ed. Unknown.

MLA

Hughes, D., D.A. Hughes and [No Value] All Wales Strategy Group. All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate. 2008 udg. Unknown. 2008.

VancouverVancouver

Hughes D, Hughes DA, All Wales Strategy Group. NV. All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate. 2008 ed. Unknown, 2008.

Author

Hughes, D. ; Hughes, D.A. ; All Wales Strategy Group., [No Value]. / All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate. 2008 ed. Unknown, 2008.

RIS

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2008/1/1

Y1 - 2008/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/Alemtuzumab%20(MabCampath)%20FAR.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

PB - Unknown

ER -